Kazia Therapeutics Ltd (KZIA) stock
KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30
$5.49+0.18 (+3.39%)
Close on Nov 18, 2026Market cap $8.89MP/E –Yield –
Kazia Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was A$7.33M, down 57.8% from the year before. The highest annual figure on record is A$20.17M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | A$7.33M | -57.8% |
| FY2024 | Jun 30, 2024 | A$17.38M | +11.7% |
| FY2023 | Jun 30, 2023 | A$15.56M | -22.8% |
| FY2022 | Jun 30, 2022 | A$20.17M | +38.7% |
| FY2021 | Jun 30, 2021 | A$14.54M | +53.2% |
| FY2020 | Jun 30, 2020 | A$9.49M | +46.6% |
| FY2019 | Jun 30, 2019 | A$6.48M | -33.8% |
| FY2018 | Jun 30, 2018 | A$9.77M | -12.2% |
| FY2017 | Jun 30, 2017 | A$11.14M | +12.6% |
| FY2016 | Jun 30, 2016 | A$9.89M | – |
See a number that looks wrong?